3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Lymphoma, T-Cell, Peripheral
3
Myelodysplastic Syndromes
2
Lymphoma, T-Cell
2
Leukemia, Myeloid, Acute
2
Uveal Melanoma
1
Neuroendocrine Tumors
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Immunoblastic Lymphadenopathy
1
Hematologic Neoplasms
1
Eye Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Neuroendocrine
1
Blast Crisis
1
Interventions
Doxorubicin
5
pembrolizumab
4
Specimen Handling
4
Radiotherapy
4
Radiation
4
Nivolumab
4
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
CTLA-4 Antigen
3
Biopsy
3
cabozantinib
2
Ifosfamide
2
tremelimumab
1
talimogene laherparepvec
1
regorafenib
1
peposertib
1
pazopanib
1
olaratumab
1
liposomal doxorubicin
1
futibatinib
1
fludarabine
1
eribulin
1
durvalumab
1
avelumab
1
aldesleukin
1
X-Rays
1
Trabectedin
1
Standard of Care
1
Quality of Life
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Histiocytoma, Malignant Fibrous
×
belinostat
×
1 year
×
Clear all
No trials found.